Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: The life study

American Journal of Hypertension

Volumn 21, Issue 6, 2008, Pages 701-707

  Palmieri, Vittorio ^a   Bella, Jonathan N ^a   Gerdts, Eva ^b   Wachtell, Kristian ^c   Papademetriou, Vasilios ^d   Nieminen, Markku S ^e   Dahlöf, Björn ^f   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; LOSARTAN;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; ETHNICITY; FEMALE; FOLLOW UP; GEOMETRY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULSE PRESSURE; STATISTICAL SIGNIFICANCE; STROKE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ARTERIES; ATENOLOL; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIAC VOLUME; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PULSE;

EID: 44349165883     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.162     Document Type: Article

References (39)

1. Stergiopulos N, Meister JJ, Westerhof N. Simple and accurate way for estimating total and segmental arterial compliance: the pulse pressure method. Ann Biomed Eng 1994; 22:392-397.
2. Celentano A, Palmieri V, Di Palma Esposito N, Pietropaolo I, Arezzi E, Mureddu GF, de Simone G. Relations of pulse pressure and other components of blood pressure to preclinical echocardiographic abnormalities. J Hypertens 2002; 20:531-537.
3. Palmieri V, Devereux RB, Hollywood J, Bella JN, Liu JE, Lee ET, Best LG, Howard BV, Roman MJ. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study. Am J Hypertens 2006; 19:601-607.
4. Gardin JM, Arnold A, Gottdiener JS, Wong ND, Fried LP, Klopfenstein HS, O'Leary DH, Tracy R, Kronmal R. Left ventricular mass in the elderly. The Cardiovascular Health Study. Hypertension 1997; 29:1095-1103.
5. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334-341.
6. Gerdts E, Papademetriou V, Palmieri V, Boman K, Bjornstad H, Wachtell K, Giles TD, Dahlöf B, Devereux RB. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2002; 89:399-402.
7. Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension 2005; 45:580-585.
8. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
9. Stergiopulos N, Segers P, Westerhof N. Use of pulse pressure method for estimating total arterial compliance in vivo. Am J Physiol 1999; 276:H424-H428.
10. Safar ME, St Laurent S, Safavian AL, Pannier BM, London GM. Pulse pressure in sustained essential hypertension: a haemodynamic study. J Hypertens 1987; 5:213-218.
11. Chemla D, Hebert JL, Coirault C, Zamani K, Suard I, Colin P, Lecarpentier Y. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. Am J Physiol 1998; 274:H500-H505.
12. Roman MJ, Ganau A, Saba PS, Pini R, Pickering TG, Devereux RB. Impact of arterial stiffening on left ventricular structure. Hypertension 2000; 36:489-494.
13. Palmieri V, Bella JN, Roman MJ, Gerdts E, Papademetriou V, Wachtell K, Nieminen MS, Dahlöf B, Devereux RB. Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens 2003; 21:781-787.
14. Shimamoto H, Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension 1996; 28:457-463.
15. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926.
16. Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, Trimarco B, Fitzgerald D, Hedner T, Duprez D, De Leeuw PW, Sever P, Battegay E, Hitzenberger G, de Luca N, Polonia P, Benetos A, Chastang C, Ollivier JP, Safar ME. Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens 2001; 19(Suppl):S15-S20.
17. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar ME. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17:660-667.
18. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlöf B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104:1248-1254.
19. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32:989-997.
20. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10:74-82.
21. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143:319-326.
22. Devereux RB, Roman JM. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques. In Laragh JH, Brenner BM (eds), Hypertension: Pathophysiology, Diagnosis, Treatment. Raven Press: NY, 1995, pp. 1969-1985.
23. Palmieri V, Bella JN, DeQuattro V, Roman MJ, Hahn RT, Dahlöf B, Sharpe N, Lau CP, Chen WC, Paran E, de Simone G, Devereux RB. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). Am J Cardiol 1999; 84:558-562.
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
25. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
26. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Wood EA, Howard BV, Welty TK, Lee ET, Fabsitz RR. Relations of Doppler stroke volume and its components to left ventricular stroke volume in normotensive and hypertensive American Indians: the Strong Heart Study. Am J Hypertens 1997; 10:619-628.
27. Collis T, Devereux RB, Roman MJ, de Simone G, Yeh JL, Howard BV, Fabsitz RR, Welty TK. Relations of stroke volume and cardiac output to body composition: the Strong Heart Study. Circulation 2001; 103:820-825.
28. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahlöf B. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 2002; 20:1445-1450.
29. Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlöf B, Roman MJ, Devereux RB. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study. J Hypertens 2001; 19:127-134.
30. Stergiopulos N, Westerhof N. Role of total arterial compliance and peripheral resistance in the determination of systolic and diastolic aortic pressure. Pathol Biol (Paris) 1999; 47:641-647.
31. de Simone G, Roman MJ, Koren MJ, Mensah GA, Ganau A, Devereux RB. Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. Hypertension 1999; 33:800-805.
32. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989; 14:14-21.
33. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens 2007; 20:378-384.
34. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
35. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
36. Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, Stanton A, Hughes A, Thom S. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006; 37:2381-2384.
37. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
38. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B, Brunner H, Laurent S. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000; 101:2601-2606.
39. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48:80-86.